Ana Medina

A Coruna, GA, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Real-world Outcomes in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck With Nivolumab: Galician Study.

Real-world Outcomes in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck With Nivolumab: Galician Study.

Journal: Anticancer research

Published: January 13, 2025

Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study.

Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study.

Journal: European urology oncology

Published: July 15, 2023

Real-world Data of Paclitaxel and Cetuximab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.

Real-world Data of Paclitaxel and Cetuximab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.

Journal: Cancer diagnosis & prognosis

Published: November 04, 2022

Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate Cancer.

Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate Cancer.

Journal: European urology

Published: December 16, 2019

PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.

PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 10, 2019

Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer.

Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 12, 2018

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.

Journal: European urology

Published: May 18, 2018

Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting.

Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting.

Journal: Therapeutic advances in medical oncology

Published: May 23, 2017

A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN).

A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN).

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 17, 2017

Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU).

Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU).

Journal: Current oncology reports

Published: November 05, 2016

Showing 1-10 of 10

Last Updated: 09/26/2026